TY - JOUR
T1 - Cytoplasmic Ezrin and Moesin Correlate with Poor Survival in Head and Neck Squamous Cell Carcinoma
AU - Schlecht, Nicolas F.
AU - Brandwein-Gensler, Margaret
AU - Smith, Richard V.
AU - Kawachi, Nicole
AU - Broughel, Darcy
AU - Lin, Juan
AU - Keller, Christian E.
AU - Reynolds, Paul A.
AU - Gunn-Moore, Frank J.
AU - Harris, Thomas M.
AU - Childs, Geoffrey
AU - Belbin, Thomas J.
AU - Prystowsky, Michael B.
N1 - Funding Information:
Acknowledgments Contract grant sponsor: National Institutes of Health; Contract grant numbers: CA103547 (to MBP), CA115243 (to NFS), CA104402 (to TJB); Contract grant sponsor: UK Biotechnology and Biological Sciences Research Council (to FGM). The present study was supported by the Department of Pathology, Albert Einstein College of Medicine/Montefiore Medical Center. We thank the participants of this study; Catherine Sarta for her time and effort spent enrolling and following participants and with data entry, Gregory Rosenblatt for his assistance with data management and Dr. Joseph Locker for preparation of Fig. 1.
PY - 2012/6
Y1 - 2012/6
N2 - Members of the 4. 1 superfamily of proteins, including ezrin, moesin, merlin, and willin regulate many normal physiologic processes such as cellular shape, motility, and proliferation. In addition, they contribute both to tumor development and tumor progression. We reported previously that strong cytoplasmic ezrin expression was independently associated with poorer patient survival. One hundred and thirty-one histologically confirmed primary head and neck squamous cell carcinomas were examined prospectively for cancer progression and survival at a large health care center in the Bronx, NY, USA. Immunohistochemical analysis of ezrin, moesin, merlin, and willin expression in tissue microarray samples of primary head and neck squamous cell carcinoma revealed a significant association of increased cytoplasmic ezrin with poor cancer survival. Global RNA analyses suggest that cancers with high cytoplasmic ezrin have a more invasive phenotype. This study supports our previous findings associating cytoplasmic ezrin with more aggressive behavior and poorer outcome and indicates the need for a multi-institutional study to validate the use of cytoplasmic ezrin as a biomarker for treatment planning in head and neck squamous cell carcinoma.
AB - Members of the 4. 1 superfamily of proteins, including ezrin, moesin, merlin, and willin regulate many normal physiologic processes such as cellular shape, motility, and proliferation. In addition, they contribute both to tumor development and tumor progression. We reported previously that strong cytoplasmic ezrin expression was independently associated with poorer patient survival. One hundred and thirty-one histologically confirmed primary head and neck squamous cell carcinomas were examined prospectively for cancer progression and survival at a large health care center in the Bronx, NY, USA. Immunohistochemical analysis of ezrin, moesin, merlin, and willin expression in tissue microarray samples of primary head and neck squamous cell carcinoma revealed a significant association of increased cytoplasmic ezrin with poor cancer survival. Global RNA analyses suggest that cancers with high cytoplasmic ezrin have a more invasive phenotype. This study supports our previous findings associating cytoplasmic ezrin with more aggressive behavior and poorer outcome and indicates the need for a multi-institutional study to validate the use of cytoplasmic ezrin as a biomarker for treatment planning in head and neck squamous cell carcinoma.
KW - Ezrin
KW - Head and neck cancer
KW - Immunohistochemistry
KW - Merlin
KW - Moesin
KW - Survival
KW - Willin
UR - http://www.scopus.com/inward/record.url?scp=84862229164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862229164&partnerID=8YFLogxK
U2 - 10.1007/s12105-011-0328-1
DO - 10.1007/s12105-011-0328-1
M3 - Article
C2 - 22228071
AN - SCOPUS:84862229164
SN - 1936-055X
VL - 6
SP - 232
EP - 243
JO - Head and Neck Pathology
JF - Head and Neck Pathology
IS - 2
ER -
